Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04484623

Acronym

DREAMM 8

Enrollment

302

Registered

2020-07-23

Start date

2020-10-01

Completion date

2029-06-25

Last updated

2026-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Keywords

Global Cohort, Belantamab Mafodotin, Relapsed/Refractory Multiple Myeloma, Pomalidomide, Dexamethasone, Bortezomib

Brief summary

This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple myeloma (RRMM).

Interventions

DRUGBelantamab mafodotin

Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate will be administered.

DRUGPomalidomide

Immunomodulatory drug (IMiD) will be administered.

DRUGDexamethasone

Synthetic glucocorticoid with anti-tumor activity will be administered.

DRUGBortezomib

Proteasome Inhibitor will be administered.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Capable of giving signed informed consent. * Male or female, 18 years or older. * Have a confirmed diagnosis of multiple myeloma (MM) as defined by the International Myeloma Working Group (IMWG) criteria. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. * Have been previously treated with at least 1 prior line of MM therapy including a lenalidomide-containing regimen and must have documented disease progression during or after their most recent therapy. (Participants treated with lenalidomide ≥10 mg daily for at least 2 consecutive cycles are eligible). * Must have at least 1 aspect of measurable disease defined as one of the following; 1. Urine M-protein excretion greater than or equal to (≥)200 milligrams (mg) per 24-hour, or 2. Serum M-protein concentration ≥0.5 grams/deciliters (g/dL) (≥5.0 g/liter \[L\]), or 3. Serum free light chain (FLC) assay: involved FLC level ≥10 mg/dL (≥100 mg/L) and an abnormal serum free light chain ratio (less than \[\<\]0.26 or greater than \[\>\]1.65) only if participant has no measurable urine or serum M spike. * Have undergone autologous stem cell transplant (ASCT) or are considered transplant ineligible. Participants with a history of ASCT are eligible for study participation provided the following eligibility criteria are met: a. ASCT was \>100 days prior to the first dose of study medication. b. No active bacterial, viral, or fungal infection(s) present * All prior treatment-related toxicities (defined by National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI-CTCAE\] version 5.0) must be less than or equal to (≤)Grade 1 at the time of enrolment, except for alopecia. * Adequate organ system functions as mentioned in the protocol. * Male and female participants agree to abide by protocol-defined contraceptive requirements.

Exclusion criteria

* Active plasma cell leukemia, symptomatic amyloidosis or active polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma proliferative disorder, and skin changes (POEMS) syndrome at the time of screening. * Prior allogeneic SCT. * Systemic anti-myeloma therapy (including chemotherapy and systemic steroids) within 14 days or five half-lives (whichever is shorter) preceding the first dose of study drug; prior treatment with a monoclonal antibody drug within 30 days of receiving the first dose of study drugs. * Plasmapheresis within 7 days prior to the first dose of study drug. * Received prior treatment with or intolerant to pomalidomide. * Received prior Beta cell maturation antigen (BCMA) targeted therapy. * Intolerant to bortezomib or refractory to bortezomib (for example; participant experienced progressive disease during treatment, or within 60 days of completing treatment, with a bortezomib-containing regimen of 1.3 mg/meter square \[m\^2\] twice weekly). * Evidence of cardiovascular risk including any of the following; 1. Evidence of current clinically significant untreated arrhythmias, including clinically significant electrocardiogram abnormalities including second degree (Mobitz type II) or third degree atrioventricular (AV) block. 2. Recent history within (3 months of screening) of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting . 3. Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system 4. Uncontrolled hypertension. * Any major surgery within the last 4 weeks. * Previous or concurrent invasive malignancy other than multiple myeloma, except: 1. The disease must be considered medically stable for at least 2 years; or 2. The participant must not be receiving active therapy, other than hormonal therapy for this disease. * Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to belantamab mafodotin or drugs chemically related to belantamab mafodotin, or any of the components of the study treatment. * Evidence of active mucosal or internal bleeding. * Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice. * Active infection requiring treatment. * Known or active human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C will be excluded unless the protocol-defined criteria are met. * Presence of active renal conditions (such as infection, severe renal impairment requiring dialysis or any other condition that could affect participant's safety). * Ongoing Grade 2 peripheral neuropathy with pain within 14 days prior to randomization or ≥Grade 3 peripheral neuropathy. * Active or history of venous and arterial thromboembolism within the past 3 months. * Contraindications to or unwilling to undergo protocol-required anti-thrombotic prophylaxis. * Current corneal disease except for mild punctate keratopathy. * Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including laboratory abnormalities) that could interfere with participant's safety, obtaining informed consent or compliance to the study procedures. * Pregnant or lactating female.

Design outcomes

Primary

Measure	Time frame	Description
Progression-Free Survival (PFS)	Up to approximately 174 weeks	PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD is defined as increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5 grams per deciliter {g/dL}\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200 milligrams per 24 hours {mg/24h}\]; participants without measurable serum \& urine M-protein levels, difference between involved \& uninvolved serum free light chains (sFLC) levels \[absolute increase \>10mg/dL\]; appearance of new lesion,\>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 centimeter (cm) in short axis.

Secondary

Measure	Time frame	Description
Overall Survival (OS)	Up to approximately 473 weeks	Overall Survival (OS) defined as the interval of time from randomization to the date of death due to any cause.
Duration of Response (DoR)	Up to approximately 473 weeks	Duration of Response (DoR) defined as the time from first documented evidence of PR or better until progressive disease (PD) or death due to any cause. Response will be based on IRC-assessment per IMWG criteria.
Minimal Residual Disease (MRD) Negativity Rate	Up to approximately 473 weeks	MRD negativity rate defined as the percentage of participants who achieve MRD negative status (as assessed by next-generation sequencing at 10\^5 threshold) at least once during the time of confirmed CR or better response based on IRC-assessment per IMWG.
Overall Response Rate (ORR)	Up to approximately 473 weeks	ORR will be defined as the percentage of participants with a confirmed partial response or better (i.e., PR, VGPR, CR, and sCR) based on IRC-assessment per IMWG criteria.
Complete Response Rate (CRR)	Up to approximately 473 weeks	Complete Response Rate (CRR), defined as the percentage of participants with a confirmed complete response (CR) or better (i.e., CR and stringent complete response (sCR)) based on IRC assessment per IMWG criteria.
Percentage of Participants With a Confirmed Very Good Partial Response (VGPR) or Better	Up to approximately 473 weeks	VGPR is defined as the percentage of participants with a confirmed VGPR or better (i.e., VGPR, CR, and sCR) based on IRC-assessment per IMWG criteria.
Time to Best Response (TTBR)	Up to approximately 473 weeks	TTBR defined as the interval of time between the date of randomization and the earliest date of achieving best response among participants with a confirmed PR or better based on IRC-assessment per IMWG.
Time to Response (TTR)	Up to approximately 473 weeks	TTR defined as the time between the date of randomization and the first documented evidence of response (PR or better) among participants who achieve a response (i.e., confirmed PR or better) based on IRC-assessment per IMWG.
Time to Progression (TTP)	Up to approximately 473 weeks	TTP defined as the time from randomization until the earliest date of PD based on IRC-assessment per IMWG criteria, or death due to PD.
Progression-Free Survival 2 (PFS2)	Up to approximately 473 weeks	PFS2 defined as time from randomization to disease progression (investigator-assessed response) after initiation of new anti-myeloma therapy or death from any cause, whichever is earlier. If disease progression after new antimyeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier.
Number of Participants With Adverse Events (AEs)	Up to approximately 473 weeks	—
Number of Participants With Clinically Significant Changes in Hematology Parameters	Up to approximately 473 weeks	Blood samples will be collected for the analysis of hematology parameters.
Number of Participants With Clinically Significant Changes in Clinical Chemistry Parameters	Up to approximately 473 weeks	Blood samples will be collected for the analysis of clinical chemistry parameters.
Number of Participants With Abnormal Ocular Findings on Ophthalmic Examination	Up to approximately 473 weeks	—
Plasma Concentrations of Belantamab Mafodotin (ADC) at Indicated Time Points	Up to approximately 473 weeks	Blood samples will be collected for PK analysis of belantamab mafodotin.
Plasma Concentrations of Monomethyl Auristatin-F With a Cysteine Linker (Cys-mcMMAF) at Indicated Time Points	Up to approximately 473 weeks	Blood samples will be collected for PK analysis of belantamab mafodotin.
Area Under Plasma Concentration-time Curve (AUC) From Time 0 to the Time of the Last Quantifiable Concentration (C(Tlast)) [AUC (0-last)] for Pomalidomide	Up to approximately 473 weeks	Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.
Area Under Plasma Concentration-time Curve (AUC) From Time 0 to End of the Dosing Interval [AUC (0-tau)] for Pomalidomide	Up to approximately 473 weeks	Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.
Maximum Concentration (Cmax) for Pomalidomide	Up to approximately 473 weeks	Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.
Time of Cmax (Tmax) for Pomalidomide	Up to approximately 473 weeks	Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.
Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Pomalidomide	Up to approximately 473 weeks	Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.
Last Time Point Where the Concentration is Above the Limit of Quantification (Tlast) for Pomalidomide	Up to approximately 473 weeks	Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin	Up to approximately 473 weeks	Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers.
Titers of ADAs Against Belantamab Mafodotin	Up to approximately 473 weeks	Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be to be further tested in screening assay, and positive samples will be further characterized for antibody titers.
Number of Participants With Maximum Post-baseline Change From Baseline in Individual Items of Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE)	Up to approximately 473 weeks	The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE.
Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by EuropeanOrganization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30)	Up to approximately 473 weeks	The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These includes five functional scales (physical functioning \[PF\], role functioning \[RF\], cognitive functioning \[CF\], emotional functioning \[EF\] and social functioning \[SF\]), three symptom scales (fatigue, pain and nausea/vomiting \[N/V\]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss \[AL\] and financial difficulties \[FD\]). Response options are 1 to 4. Scores are averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represents better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represents significant symptomatology. Baseline is defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline is calculated by subtracting Baseline value from the post-dose visit value.
Change From Baseline in Quality of Life Questionnaire 20-item Multiple Myeloma Module (QLQMY20)	Up to approximately 473 weeks	The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score for Future Perspective and Body Image represents a high/healthy level of functioning.
Change From Baseline in HRQoL as Measured by EORTC IL52	Up to approximately 473 weeks	The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. For the EORTC IL52, disease symptoms domain of the QLQ-MY20 will be used for bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score for Future Perspective and Body Image represents a high/healthy level of functioning.

Countries

Australia, Brazil, China, Czechia, France, Germany, Greece, Israel, Italy, Japan, New Zealand, Poland, Russia, South Korea, Spain, Turkey (Türkiye), United Kingdom, United States

Contacts

STUDY_DIRECTORGSK Clinical Trials

GlaxoSmithKline

Participant flow

Pre-assignment details

The results presented are until the primary completion date. Additional results will be provided within a year of study completion.

Participants by arm

Arm	Count
Belantamab Mafodotin+Pomalidomide+Dexamethasone Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received intravenous (IV) infusion of 2.5 milligram (mg)/kilogram (kg) belantamab mafodotin on Day 1 of Cycle 1 and 1.9 mg/kg on Day 1 of Cycle 2 onwards in each 28-day cycle, in combination with oral 4 mg per day Pomalidomide capsule on Days 1 to 21 of each 28-day cycle; and oral 40 mg per day Dexamethasone tablet on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, initiation of another anti-myeloma therapy or end of study, whichever occurs first.	155
Pomalidomide+Bortezomib+Dexamethasone Participants with RRMM received oral 4 mg per day Pomalidomide capsule on Days 1 to 14 of each 21-day cycle, in combination with subcutaneous (SC) injection of 1.3 mg/meter\^2(m\^2) Bortezomib on Days 1, 4, 8, 11, of each 21-day cycle for Cycles 1 through 8, and on Days 1, 8, of each 21-day cycle for Cycles 9+, and oral 20 mg Dexamethasone tablet on Days 1, 2, 4, 5, 8, 9, 11, 12, of each 21-day cycle for Cycles 1 through 8 and then on Days 1, 2, 8, 9, every 3 Weeks (Q3W) from Cycles 9 onwards until disease progression, death, unacceptable toxicity, withdrawal of consent, initiation of another anti-myeloma therapy or end of study, whichever occurs first.	147
Total	302

Baseline characteristics

Characteristic	Belantamab Mafodotin+Pomalidomide+Dexamethasone	Pomalidomide+Bortezomib+Dexamethasone	Total
Age, Continuous	65.5 YEARS STANDARD_DEVIATION 8.56	66.7 YEARS STANDARD_DEVIATION 10.03	66.1 YEARS STANDARD_DEVIATION 9.31
Race/Ethnicity, Customized Others	22 Participants	20 Participants	42 Participants
Race/Ethnicity, Customized White	133 Participants	127 Participants	260 Participants
Sex: Female, Male Female	56 Participants	65 Participants	121 Participants
Sex: Female, Male Male	99 Participants	82 Participants	181 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	48 / 155	54 / 147
other Total, other adverse events	148 / 150	130 / 145
serious Total, serious adverse events	95 / 150	65 / 145

Outcome results

Primary

Progression-Free Survival (PFS)

PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD is defined as increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5 grams per deciliter {g/dL}\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200 milligrams per 24 hours {mg/24h}\]; participants without measurable serum & urine M-protein levels, difference between involved & uninvolved serum free light chains (sFLC) levels \[absolute increase \>10mg/dL\]; appearance of new lesion,\>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 centimeter (cm) in short axis.

Time frame: Up to approximately 174 weeks

Population: Intent-to-Treat (ITT) Population included all randomized participants whether or not randomized treatment was administered.

Arm	Measure	Value (MEDIAN)
Belantamab Mafodotin+Pomalidomide+Dexamethasone	Progression-Free Survival (PFS)	NA Months
Pomalidomide+Bortezomib+Dexamethasone	Progression-Free Survival (PFS)	12.7 Months

p-value: <0.00195% CI: [0.37, 0.73]Log Rank

Secondary

Area Under Plasma Concentration-time Curve (AUC) From Time 0 to End of the Dosing Interval [AUC (0-tau)] for Pomalidomide

Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.